| Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline J Mikhael, N Ismaila, MC Cheung, C Costello, MV Dhodapkar, S Kumar, ... Journal of Clinical Oncology 37 (14), 1228-1263, 2019 | 267 | 2019 |
| Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial OA O'Connor, JK Lue, A Sawas, JE Amengual, C Deng, M Kalac, L Falchi, ... The Lancet Oncology 19 (2), 257-266, 2018 | 123 | 2018 |
| Safety and efficacy of thrombopoietin‐receptor agonists in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials A Prica, M Sholzberg, R Buckstein British journal of haematology 167 (5), 626-638, 2014 | 71 | 2014 |
| Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma P Skrabek, S Assouline, A Christofides, D MacDonald, A Prica, R Sangha, ... Current Oncology 26 (4), 253-265, 2019 | 50 | 2019 |
| Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study H Abdel-Qadir, N Sabrie, D Leong, A Pang, PC Austin, A Prica, ... Journal of clinical oncology 39 (31), 3453-3462, 2021 | 48 | 2021 |
| Evaluation of an educational program for the caregivers of persons diagnosed with a malignant glioma R Cashman, LJ Bernstein, D Bilodeau, G Bowett, B Jackson, M Yousefi, ... Canadian Oncology Nursing Journal/Revue canadienne de soins infirmiers en …, 2007 | 34 | 2007 |
| Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis A Prica, K Chan, MC Cheung British journal of haematology 158 (5), 600-607, 2012 | 29 | 2012 |
| Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—The 5C study: A study protocol for a randomised … MTE Puts, T Hsu, C Mariano, J Monette, S Brennenstuhl, E Pitters, J Ray, ... BMJ open 9 (5), e024485, 2019 | 28 | 2019 |
| Impact of geriatric assessment and management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C trial M Puts, N Alqurini, F Strohschein, R Koneru, E Szumacher, C Mariano, ... Journal of Clinical Oncology 41 (4), 847, 2023 | 27 | 2023 |
| Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced‐stage follicular lymphoma: A cost‐effectiveness analysis A Prica, K Chan, M Cheung Cancer 121 (15), 2637-2645, 2015 | 27 | 2015 |
| S262: The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9–engineered CAR T cells in patients with relapsed/refractory (R/R … SP Iyer, RA Sica, PJ Ho, B Hu, J Zain, A Prica, WK Weng, YH Kim, ... HemaSphere 6, 163-164, 2022 | 26 | 2022 |
| Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras AY Li, EG Atenafu, RS Bernard, E Masih-Khan, D Reece, N Franke, ... Bone Marrow Transplantation 55 (3), 578-585, 2020 | 25 | 2020 |
| Effect of PET/CT on the management and outcomes of participants with Hodgkin and aggressive non-Hodgkin lymphoma: a multicenter registry U Metser, A Prica, DC Hodgson, M Mozuraitis, M Eberg, V Mak, B Green, ... Radiology 290 (2), 488-495, 2019 | 25 | 2019 |
| Rituximab in lymphoma and chronic lymphocytic leukaemia: a practice guideline A Prica, F Baldassarre, LK Hicks, K Imrie, T Kouroukis, M Cheung Clinical Oncology 29 (1), e13-e28, 2017 | 24 | 2017 |
| Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study A Vijenthira, K Chan, MC Cheung, A Prica The Lancet Haematology 7 (2), e146-e156, 2020 | 23 | 2020 |
| Financial impact of cancer drug wastage and potential cost savings from mitigation strategies CYW Leung, MC Cheung, LF Charbonneau, A Prica, P Ng, KKW Chan Journal of Oncology Practice 13 (7), e646-e652, 2017 | 23 | 2017 |
| SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma AF Herrera, H Li, SM Castellino, SC Rutherford, K Davison, AG Evans, ... Blood 136, 23-24, 2020 | 21 | 2020 |
| Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines P Thavendiranathan, C Houbois, TH Marwick, T Kei, S Saha, K Runeckles, ... European Heart Journal-Cardiovascular Pharmacotherapy 9 (6), 515-525, 2023 | 19 | 2023 |
| Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. E Tseng, R Alhusayen, S Sade, R Buckstein, A Prica British Journal of Haematology 169 (4), 2015 | 17 | 2015 |
| Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus … A Vijenthira, J Kuruvilla, M Crump, M Jain, A Prica Journal of Clinical Oncology 41 (8), 1577-1589, 2023 | 15 | 2023 |
